Matt Henn

Company: Seres Therapeutics

Job title: Executive Vice Pesident & Chief Scientific Officer

Seminars:

Panel Discussion: Evaluating Translational Success in Microbiome Drug Development 9:00 am

Highlighting translational gaps and strategies to overcome these Unpacking regulatory expectations on mechanisms of actionRead more

day: Conference Day Two, 7:30 - 10:00

Breakthrough in GI-Derived Bloodstream Infection Reduction: SER-155’s FDA Designation 10:30 am

Highlighting the significant reduction in bacterial bloodstream infections demonstrated in Phase 1b trials of SER-155 and its impact on patient outcomes Discussing the significance of FDA breakthrough therapy designation and fast track status for expedited development and regulatory collaboration Exploring the future development plans for SER-155, including its potential applications in various high-risk patient populations Read more

day: Conference Day Two, Track One, AM